• Advancing gastrointestinal health naturally

    Our Gastrointestinal ReProgramming (GaRP) product is a microbiome-targeted multi-component dietary supplement that has been designed to address the primary underlying factors associated with gastrointestinal disorders. More >>

  • Exclusive Global License Agreement with Zoetis

    Anatara has signed an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach. More >>

  • ANATARA 2018 ANNUAL REPORT

    Anatara is pleased to release its 2018 Annual Report to its shareholders. Please click here for the ASX announcement.

  • Successful Dietary Supplement Proof of Concept Studies

    Anatara’s unique Gastrointestinal ReProgramming (GaRP) dietary supplement has been shown to significantly reduce inflammation and protect and maintain gut integrity in recent in vitro studies. More >>

Company description

Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products.

Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Annual report

Anatara Annual Report

News

..
More News

Events

More Events

Investors

Investors Home

Pause